Infinity to Present at the H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

Infinity Pharmaceuticals, a clinical-stage biotechnology company, announced its participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for on-demand listening starting at 7:00 am ET on March 9, 2021. Infinity is developing eganelisib, an innovative immuno-oncology therapy targeted at reprogramming macrophages to combat cancer. Current clinical trials include combinations of eganelisib with well-known drugs like Opdivo, Tecentriq, and Abraxane for various cancer types. More details can be found on Infinity's website.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, today announced that management will present at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9^th – Wednesday, March 10^th, 2021.

The presentation will be available for on-demand listening at 7:00 am ET on Tuesday, March 9^th, 2021 or via the following link: https://journey.ct.events/view/2f6707ba-a83b-4a2e-adef-7170771bc186

The webcast of the presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005284/en/

FAQ

What conference will Infinity Pharmaceuticals present at in March 2021?

Infinity Pharmaceuticals will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

When will the presentation by Infinity Pharmaceuticals be available for listening?

The presentation will be available for on-demand listening starting at 7:00 am ET on March 9, 2021.

What is eganelisib developed by Infinity Pharmaceuticals?

Eganelisib is a potential first-in-class oral immuno-oncology therapy targeting macrophage reprogramming to address immune suppression in cancer.

Which drugs are being studied in combination with eganelisib?

Eganelisib is being studied in combination with Opdivo, Tecentriq, and Abraxane in various clinical trials.

Where can I find more information about Infinity Pharmaceuticals?

More information about Infinity Pharmaceuticals can be found on their website at www.infi.com.